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A B S T R A C T   
Introduction: Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved for hallucinations and delusions associated with Parkinson’s disease psy-
chosis (PDP). We present durability of response with pimavanserin in patients with PDP for an additional 4 weeks of treatment. 
Methods: This was an open-label extension (OLE) study in patients previously completing one of three double-blind, placebo-controlled (Core) studies. All patients 
received pimavanserin 34 mg once daily. Efficacy assessments included the Scale for the Assessment of Positive Symptoms (SAPS) PD and H + D scales, Clinical 
Global Impression (CGI) Improvement and Severity scales and Caregiver Burden Scale (CBS), through 4 weeks in the OLE. Safety assessments were conducted at each 
visit. 
Results: Of 459 patients, 424 (92.4%) had a Week 4 efficacy assessment. At Week 4 (10 weeks total treatment), SAPS-PD mean (standard deviation) change from OLE 
baseline was − 1.8 (5.5) and for SAPS-H + D was − 2.1 (6.2) with pimavanserin 34 mg. Patients receiving placebo during the Core studies had greater improvements 
(SAPS-PD -2.9 [5.6]; SAPS-H + D − 3.5 [6.3]) during the OLE. For participants treated with pimavanserin 8.5 or 17 mg during the Core studies, further improvement 
was observed during the OLE with pimavanserin 34 mg. The mean change from Core Study baseline for SAPS-PD score was similar among prior pimavanserin 34 mg 
and prior placebo-treated participants (− 7.1 vs. − 7.0). The CGI-I response rate (score of 1 or 2) at Week 4 was 51.4%. Adverse events were reported by 215 (46.8%) 
patients during the first 4 weeks of OLE. The most common AEs were fall (5.9%), hallucination (3.7%), urinary tract infection (2.8%), insomnia (2.4%), and pe-
ripheral edema (2.2%) 
Conclusions: Patients previously on pimavanserin 34 mg during three blinded core studies had durability of efficacy during the subsequent 4 week OLE SAPS-PD 
assessment. Patients previously on blinded placebo improved after 4 weeks of OL pimavanserin treatment. These results in over 400 patients from 14 countries 
support the efficacy of pimavanserin for treating PDP.   
1. Introduction 
Psychotic symptoms are a common occurrence for patients with 
Parkinson’s disease (PD), which develop in approximately 50% of pa-
tients over the course of their disease [1,2]. The onset and progression of 
these symptoms complicate PD management and are linked to increased 
co-morbidity [1]. Parkinson’s disease psychosis (PDP) is itself a major 
risk factor for hospitalization, nursing home placement, and mortality 
[3–7]. Prior to the approval of pimavanserin, the only pharmacological 
treatment options for PDP in the U.S. were off-label use of antipsychotics 
or acetylcholinesterase inhibitors [8]. However, these drugs lack proven 
efficacy, may worsen motor symptoms, have limiting side effects, 
and/or require blood monitoring for significant risks [9–16]. 
The selective 5-HT2A receptor inverse agonist/antagonist pima-
vanserin is devoid of dopaminergic, histaminergic, adrenergic, or 
muscarinic activity in animal models [17]. In the Phase 3, 
placebo-controlled pivotal study (Study 020), pimavanserin 34 mg once 
daily (equivalent to 40 mg pimavanserin tartrate) exhibited significant 
* Corresponding author. Parkinson’s Disease and Movement Disorders Center, 951 Northwest 13th Street, Building 5-E Boca Raton, FL. 
E-mail address: isaacson@parkinsonscenter.org (S.H. Isaacson).  
Contents lists available at ScienceDirect 
Parkinsonism and Related Disorders 
journal homepage: www.elsevier.com/locate/parkreldis 
https://doi.org/10.1016/j.parkreldis.2021.04.012 
Received 14 February 2020; Received in revised form 26 March 2021; Accepted 10 April 2021   
Parkinsonism and Related Disorders 87 (2021) 25–31
26
antipsychotic effects (improvement in hallucinations and delusions) 
with secondary endpoints demonstrating improved sleep and a reduc-
tion in caregiver burden over the 6-week blinded treatment period, was 
well tolerated, and did not worsen motor function [18]. Pimavanserin 
was approved in the U.S. for the treatment of hallucinations and de-
lusions associated with PDP in April 2016. The long term evaluation of 
the safety and tolerability of the entire OLE population has been sepa-
rately reported [19]. In this analysis of the Phase 3 open-label extension 
(OLE) study, the efficacy of pimavanserin 34 mg once daily was evalu-
ated in >400 patients worldwide with PDP who continued treatment 
from three Core double-blind, placebo-controlled studies or a previous 
extension study using the prespecified efficacy endpoint SAPS-PD (the 
Core study primary endpoint) after 4 weeks of OLE treatment. 
2. Methods 
The study was conducted according to the ethical principles of Good 
Clinical Practices, the International Council for Harmonisation of 
Technical Requirements for Pharmaceuticals for Human Use; United 
States Code of Federal Regulations; and World Medical Association- 
Declaration of Helsinki. Institutional Review Board or Ethics Commit-
tee approval for the protocol and the Informed Consent Form was ob-
tained at each clinical site. Written approval of these documents was 
obtained from each patient and caregiver before any study procedures 
were performed. This study was registered at clinicaltrials.gov: 
NCT00550238. 
2.1. Study design 
This is an analysis of the efficacy results of a long-term, single arm, 
OLE of previous placebo-controlled studies or previous OLE studies. This 
paper describes the efficacy assessments completed during three 6 week, 
placebo-controlled (Core) studies through the initial 4 weeks of the OLE. 
Clinical sites in North America, Europe, and India enrolled patients after 
completion of treatment with pimavanserin or placebo for 6 weeks in 
one of three, Core double-blind, randomized, placebo-controlled Phase 3 
clinical studies (ACP-103-012, NCT00477672; ACP-103-014, 
NCT00658567; or ACP-103-020, NCT01174004). Three additional pa-
tients who were enrolled did not participate in one of these studies, one 
from a previous OLE (Study 010; NCT01518309) (Fig. 1). 
For patients who enrolled within 1 week of completing a double- 
blind study (Core Study), assessments performed at the final double- 
blind visit of the Core studies (Week 6 for studies 012, 014, and 020) 
or the previous OLE study (Study 010) served as baseline for this 4-week 
OLE. Thus, no additional baseline evaluations were required except for a 
medical history and completion of a baseline Resource Utilization in 
Dementia [RUD]-Lite assessment [20]. For patients who were not 
enrolled within 1 week of completing a Core, all baseline assessments 
were required before study entry. A caregiver was required to accom-
pany the patient to all visits to provide information to study staff 
regarding the patient’s symptoms, and to complete a questionnaire to 
assess caregivers’ quality of life (Zarit Caregiver Burden Scale) [21]. 
Following baseline assessments, pimavanserin 34 mg was taken orally 
by the patient once daily. During the OLE, patients remained blinded to 
the original treatment allocation from the double-blind Core studies. 
2.2. Patient selection 
Men or women who had completed a previous Core double-blind 
study with pimavanserin within the past 28 days were eligible if the 
Investigator determined they could benefit from continued treatment 
with pimavanserin. Patients previously had satisfied eligibility criteria 
from the Core studies. Patients were required to be oriented to time, 
person, and place. All patients were required to be willing and able to 
provide informed consent and to have a caregiver who could provide 
informed consent. The caregiver had to agree to accompany the patient 
Fig. 1. Disposition of patients from Core double- 
blind, placebo-controlled studies eligible for open- 
label (OLE) study. 
* Represents number of patients from each Core 
Study who entered the 015 OLE study. 
† Two patients were in screening for Study 020 when 
enrollment was closed and were offered open-label 
treatment in Study 015, and one patient entered the 
open-label 015 study from Study 010 (NCT01518309) 
PBO = placebo.   
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to all study visits. Women had to be of non-childbearing potential during 
the study or agree to use a clinically acceptable method of contraception 
during the study. Patients were required to have psychotic symptoms of 
at least moderate severity consistent with established diagnostic criteria 
for PDP [22], which occurred at least weekly in the month prior to the 
start of blinded therapy. Improvement of symptoms during the previous 
double-blind Core studies of pimavanserin was not required for entry 
into the OLE study. Doses of dopaminergic drugs were maintained at a 
stable level throughout the Core study and during the 4 week efficacy 
assessment. 
Patients were excluded for any clinically significant medical illness 
that might interfere with the conduct of the study; use of any prohibited 
or restricted medications; current use of medications known to prolong 
the QT interval; a baseline electrocardiogram (ECG) with Bazett’s cor-
rected QT > 460 msec for males or >470 msec for females; or allergy or 
sensitivity to pimavanserin or other drugs of the same class. 
2.3. Study assessments 
Symptoms of psychosis were measured on subscales of the Scale for 
the Assessment of Positive Symptoms (SAPS) in North America by cen-
tral, blinded, independent raters (MedAvante, Inc.) and outside North 
America by qualified raters at each site trained and certified to admin-
ister the SAPS in their native language. The SAPS-PD (modified 9-item 
SAPS hallucinations and delusions subscales) and the SAPS-H + D 
(combined 20-item SAPS hallucinations and delusions subscales) [23, 
24], were evaluated at Week 4 of the OLE. The Clinical Global 
Impression-Severity and -Improvement (CGI-S and CGI-I) scales [25] 
and the Caregiver Burden Scale (CBS) were scheduled after 2 and 4 
weeks of the OLE. Unscheduled study visits were allowed at any time. 
Patients who terminated the study at any time other than a planned 
study visit were required to have an end-of-study evaluation (early 
termination visit). At each study visit, physical and neurological exam-
inations, vital signs (blood pressure and heart rate), standard clinical 
laboratory tests (chemistry, hematology, urinalysis), 12-lead ECG, and 
adverse events (AEs) were assessed. 
2.4. Statistical Analysis 
SAPS-H + D and -PD, and CGI-S, CGI-I, and CBS assessments were 
summarized through Week 4 of the OLE. Mean changes in efficacy pa-
rameters were evaluated from Core study baseline and from OLE base-
line. Change from OLE baseline to OLE Week 4 was analyzed with a 
paired t-test with the null hypothesis of no change. Changes from 
double-blind baseline to OLE Week 4 were analyzed with t-tests 
comparing group means for placebo vs. pimavanserin <34 mg, placebo 
vs. pimavanserin 34 mg, and pimavanserin <34 mg vs. pimavanserin 34 
mg. Descriptive statistics were used to summarize the data, including 
number of patients, mean, median, standard deviation (SD), standard 
error of the mean (SE), minimum and maximum for continuous mea-
surements and number and percentage of patients in each level of a 
categorical measurement. CGI-I responders were defined as having a 
score of 1 or 2 (very much improved or much improved). Adverse events 
(AEs) were summarized through the first 4 weeks of the OLE. 
3. Results 
Patient data were collected between July 2007 and May 2018 from 
114 clinical sites in 14 countries. This report summarizes all efficacy 
endpoints for a total of 10 weeks which includes the 6 week placebo 
controlled phase (Core Study) plus the first 4 weeks of the OLE. Of 538 
patients who were eligible to enroll, 459 entered the OLE study (Fig. 1); 
39 subjects terminated the study in the first 4 weeks with 424 (92.4%) 
patients having a Week 4 OLE efficacy assessment. Withdrawals were 
primarily due to adverse events (14, 3.1%) or withdrawal of consent (17, 
3.7%). The mean (median) time from completion of the Core Studies to 
enrollment in the OLE was 5.2 (1.0) days. 
Baseline demographics and disease characteristics are shown for all 
patients combined, regardless of treatment arm, from previous studies. 
At baseline, the mean (SD) age was 71.2 (8.2) years, 92.2% were white, 
and 61.7% were male (Supplemental Table 1). Over 80% of patients 
were at least 65 years and 31% were over 75 years of age. Over two- 
thirds of patients were from North America. At baseline, mean (SD) 
SAPS-PD, SAPS-H + D, and CGI-S scores for all patients were 9.2 (6.8), 
10.3 (8.0), and 3.3 (1.3), respectively. At baseline, 458 (99.8%) patients 
had a medical history of a psychiatric disorder including visual hallu-
cinations (88.0%), delusions (65.4%), and auditory hallucinations 
(46.2%). 
3.1. Durability of antipsychotic response 
SAPS data are based on the Core study period and the first 4 weeks of 
the OLE, and are presented as either the change from Core or OLE 
baseline (up to 10 weeks total treatment duration). In the overall pop-
ulation, the mean (SD) change from OLE baseline to OLE Week 4 for the 
SAPS-PD score was − 1.8 (5.5), denoting improvement (Table 1). Sig-
nificant improvements were observed from OLE baseline to OLE Week 4 
for most comparisons (Supplemental Table 2). No significant changes 
from double-blind baseline to OLE Week 4 were observed (Supplemental 
Table 3). Among participants entering the OLE study having received 
placebo in the Core Study Period, the mean change from OLE baseline to 
OLE Week 4 in the SAPS-PD was − 2.9 (5.6). For participants previously 
dosed with pimavanserin 34 mg, the mean change from OLE baseline to 
OLE Week 4 for the SAPS-PD was − 0.8 (5.6). The mean (SD) change 
from Core Study baseline for SAPS-PD scores were similar among prior 
pimavanserin 34 mg and prior placebo-treated participants (− 7.1 vs. 
− 7.0). A similar pattern of improvement was also noted in patients 
switched from prior pimavanserin doses <34 mg–34 mg (Fig. 2A). No 
notable differences were observed for mean change from OLE baseline to 
OLE Week 4 in the SAPS-PD between patients treated in North America 
[-1.6 (6.0)] vs. outside North America [-2.0 (4.3)]. Mean (SD) SAPS-H +
D scores decreased from OLE baseline to OLE Week 4 in the overall 
population [-2.1 (6.2)], in those receiving prior placebo [-3.5 (6.3)], and 
in those receiving prior pimavanserin 34 mg [-1.2 (6.3)]. At OLE week 4, 
mean (SD) change from core baseline was similar among prior pima-
vanserin 34 mg and prior placebo-treatment participants (− 8.3 vs. − 8.2) 
(Fig. 2B). At baseline, the mean Global SAPS-H + D (GSAPS-H +D) score 
was 3.9 (2.6), and at OLE Week 4, a mean change from OLE baseline of 
− 0.7 (2.2) points was observed. 
Patients dosed with placebo in Core double-blind studies 
Table 1 
Baseline and mean (standard deviation) change from OLE baseline for SAPS-PD, 
SAPS-H + D, SAPS-H, SAPS-D, CGI-S, and Caregiver Burden Scale (Safety 
analysis set).   
N Mean (SD) N Mean (SD) Change 
SAPS-PD     
OLE Baseline 454 9.2 (6.8)   
Week 4 390 7.1 (6.2) 389 − 1.8 (5.5) 
SAPS-H + D     
OLE Baseline 454 10.3 (8.0)   
Week 4 390 7.8 (6.9) 389 − 2.1 (6.2) 
SAPS-H     
OLE Baseline 454 6.8 (5.0)   
Week 4 392 5.4 (4.9) 391 − 1.2 (4.4) 
SAPS-D     
OLE Baseline 455 3.4 (4.4)   
Week 4 390 2.4 (3.4) 390 − 0.9 (3.2) 
CGI-S     
OLE Baseline 456 3.3 (1.3)   
Week 4 424 2.8 (1.2) 423 − 0.4 (1.0) 
Caregiver Burden     
OLE Baseline 453 28.2 (17.3)   
Week 4 414 28.0 (17.4) 412 0 (7.6)  
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experienced a change (improvement) from OLE baseline of − 2.1 (4.2) in 
the mean SAPS-H score at OLE Week 4. Patients previously dosed with 
pimavanserin 34 mg experienced a change from OLE baseline of − 0.4 
(4.6). Patients previously dosed with placebo had a change from OLE 
baseline in the mean SAPS-D score at OLE Week 4 of − 1.4 (3.3), and 
patients previously dosed with pimavanserin 34 mg had a change from 
OLE baseline of − 0.8 (3.0). Overall, improvement in the SAPS-H and 
SAPS-D scores that was observed during the Core double-blind treat-
ment persisted through OLE Week 4 of the OLE, while scores improved 
among patients switched from placebo to pimavanserin. 
For all patients, the mean (SD) CGI-S score at OLE baseline was 3.3 
(1.3) denoting mild symptoms. The mean change from OLE baseline to 
OLE Week 4 for the CGI-S was − 0.4 (1.0) indicating that the improve-
ment seen in Core studies over baseline was maintained (Table 1 and 
Fig. 3A). For CGI-I, the mean (SD) score at Week 2 and Week 4 of the 
OLE was 2.8 (1.3) and 2.6 (1.2), respectively (Fig. 3B). The proportion of 
CGI-I responders (very much improved or much improved) was 42.5% at 
Week 2 and 51.4% at Week 4. The mean CBS score remained stable, with 
a mean (SD) change from OLE baseline through Week 4 of the OLE of 0.0 
(7.6) (Fig. 3C), and the proportion of caregivers with little or no burden 
on the CBS of 39.3% at Week 4 of the OLE. 
3.2. Tolerability 
Following 4 weeks of OLE treatment, AEs were reported by 215 
(46.8%) patients (Table 2). Twenty-seven (5.9%) patients had an AE 
that resulted in discontinuation of the study or study drug. The majority 
of AEs were of mild or moderate intensity, but 7 (1.5%) patients had 
serious AEs with the most common being pneumonia 0.4%, and pre-
syncope, syncope, acute respiratory failure, chronic obstructive pul-
monary disease, pulmonary embolism and deep vein thrombosis all at 
0.2%. The most common AEs were fall (5.9%), hallucination (3.7%), 
urinary tract infection (2.8%), insomnia (2.4%), and peripheral edema 
(2.2%) (Table 2). No clinically relevant changes were observed for 
serum chemistry, hematology or urinalysis or for ECG findings. 
Fig. 2. Mean (SE) change from Core baseline in SAPS-PD (Panel A) and SAPS-H + D (Panel B); 6 weeks placebo controlled (Core) + 4 weeks open label extension.  
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4. Discussion 
This single arm OLE study demonstrated that the effects of pima-
vanserin 34 mg once daily on psychotic symptoms seen in placebo 
controlled studies was maintained for an additional 4 weeks in >400 
patients with PDP worldwide. Among those who switched from placebo 
to 34 mg pimavanserin in the OLE study, mean scores improved to the 
same level as the 34 mg pimavanserin group over the next 4 weeks of the 
OLE study. Those from <34 mg groups (8.5 mg and 17 mg) demon-
strated a more modest improvement in the SAPS-PD score when 
Fig. 3. Mean (SE) change from Core baseline for CGI-S (A), CGI-I (B), and Caregiver Burden Score (C).  
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switched to 34 mg. A durable response with 34 mg pimavanserin was 
observed for SAPS-PD and SAPS H + D scores at OLE Week 4 that was 
maintained among patients who entered the OLE study from the 6-week 
pimavanserin 34 mg arm in the Core blinded trials. 
In this OLE study, the mean change in SAPS-PD at OLE Week 4 was 
− 2.9 points among patients on placebo in the double-blind studies; this 
was comparable to the treatment effect observed for pimavanserin 34 
mg over placebo in 6-week Core blinded studies of pimavanserin [19, 
26]. The slope of the curves for pimavanserin <34 mg–34 mg and 
pimavanserin 34 mg–34 mg groups during the OLE are similar, reflect-
ing continuing improvement in SAPS-PD from the Core Studies into the 
OLE. The difference in mean scores between these 2 active treatment 
groups likely reflects the lower dose of 8.5 or 17 mg pimavanserin used 
in the Core studies. The more marked decrease in the placebo to pima-
vanserin 34 mg group during the OLE extension reflects the effects of 
active drug treatment during the OLE. The SAPS-PD scale retains the 
reliability, sensitivity to change, and effect size of the larger SAPS-H +
D, with reduced score variability. Regression analyses using the 
SAPS-PD scale indicated that a clinically meaningful change in the CGI-I 
scale was associated with a 2.33-point change in the SAPS-PD score 
[24]. Thus, the results obtained in this OLE are consistent with a clini-
cally meaningful improvement. Of interest, during the OLE, some 
baseline patients were less severely affected regarding SAPS-PD and 
SAPS-H + D because of previous treatment with pimavanserin. 
Prior to the availability of pimavanserin, treatment approaches for 
PDP have included a reduction or simplification of anti-Parkinson’s 
medications (a strategy that may worsen motor symptoms and increase 
OFF time), discontinuation of non-essential CNS-active drugs, addition 
of cholinesterase inhibitors in cognitively impaired patients, and the 
addition of antipsychotics with limited parkinsonian side effects (que-
tiapine or clozapine medication) [27,28]. At least 30% of PD patients 
[29], and 50% of PDP patients will start antipsychotic drugs over an 
extended period [30]. However, a significant increase in mortality is 
reported with the use of other antipsychotics in patients with PDP [14], 
necessitating caution with their use [14]. In addition, with the exception 
of clozapine and pimavanserin, objective evidence is lacking for efficacy 
to improve psychotic symptoms with the use of other antipsychotics in 
PDP patients, and clozapine requires regular blood monitoring due to 
the risk of agranulocytosis [11]. 
Previous studies have shown that the caregiver burden increases as 
symptoms of psychosis become more severe in patients with PDP [31] 
and caregiver burden is worse in PD patients with psychosis compared 
with those without [32]. Among PD patients, psychosis was one of the 
primary determinants of caregiver burden [33]. Results from this study 
show that over the first 4 weeks of this study, the CBS score remained 
stable with no worsening. 
Limitations of this study were its single arm OL design and the lack of 
a comparison group. Only descriptive statistics were performed, and 
direct comparisons between change from OLE baseline to endpoint be-
tween groups were not possible for those previously on pimavanserin 
versus placebo. Another limitation is selection bias that could have 
resulted from the non-random selection of patients for the OLE. These 
results provide the first efficacy data from extended treatment with 
pimavanserin in a population of patients with PDP, and patients 
remained blinded to treatment allocation in the Core studies during the 
4-week OLE. The results substantiate that the treatment response as 
measured by the SAPS-PD during Core double-blind, randomized studies 
with pimavanserin 34 mg is maintained during continued OLE treatment 
for a total of 10 weeks. 
Overall, the durability of response and sustained improvement in the 
severity of psychotic symptoms seen at the end of the Core studies was 
maintained as assessed with the SAPS-PD at Week 4 of the OLE. Im-
provements also were seen in CBS and CGI scales over the same time 
period suggesting that the effects on psychosis were clinically mean-
ingful to caregivers as well as clinicians. Patients initially randomized to 
placebo and switched to pimavanserin for the OLE showed improvement 
that was comparable to patients receiving pimavanserin for the entire 10 
weeks. In this study, the evaluation of >400 patients and the inclusion of 
enrolling sites worldwide provides the largest assessment of treatment of 
PDP to date. These findings support the efficacy of pimavanserin in 
treating hallucinations and delusions associated with PDP, and provide 
additional efficacy data up to 10 weeks. 
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